燃石医学品牌怎么样申请店铺

我要投票

燃石医学在基因检测行业中的票数：576 更新时间：2025-08-23

燃石医学是哪个国家的品牌？「燃石医学」是北京博宁洛克生物科技有限公司旗下著名品牌。该品牌发源于广东省广州市，由创始人汉 * 生在2014年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力燃石医学品牌出海！将品牌入驻外推网，定制燃石医学品牌推广信息，可以显著提高燃石医学产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

燃石医学成立于2014年3月，在北京、上海、广州建设有超过10000平方米的检验所、研发中心和GMP车间。燃石医学专注于肿瘤患者个体化治疗指导，以二代测序及医学生物信息学为核心，常规肿瘤分子病理检测为基石，打造肿瘤个体化治疗临床检测服务及科研一站式解决方案。

燃石医学拥有一支专业的生物信息学分析和研发队伍、以及在运营管理方面的业内团队。燃石医学更是一家拥有临床医学部的第三方临床检验机构。公司成立之初，便获得了风险投资机构北极光创投及联想之星4300万人民币的联合投资。燃石医学将这笔资金投放在实验室建设和产品研发上，一份耕耘一份收获，燃石医学创始人汉雨生带领着燃石团队，在肿瘤个体化治疗临床转化的道路上披荆斩棘，推动了二代测序技术在肿瘤临床诊断领域的转化。

目前，燃石医学已针对不同癌种、不同临床阶段开发了30余种检测产品，涉及肿瘤早筛、肿瘤良恶性判断、肿瘤靶向用药伴随检测、肿瘤复发监控及肿瘤遗传检测。

同时，燃石医学积极寻求与国内医疗机构、国际设备商、药企的深度合作，以强大的研发能力、出色的产品设计及优异的产品性能，赢得了众多医学专家及行业领导公司的青睐，已经与Illumina、阿斯利康制药、Agilent、CTONG达成战略合作。

此外，燃石医学提供一站式NGS平台解决方案，推进NGS检测落地医院病理科，惠及更多肿瘤患者。目前，燃石是通过国家食品药品监督管理总局（CFDA）审核进入《创新医疗器械特别审批程序》的肿瘤应用方向NGS公司，更已于近期获得CFDA发出的首张基于Illumina测序平台肿瘤应用方向NGS检测产品的《医疗器械注册申请受理通知书》。

精准医疗时代刚刚来临，预示着我们的长途跋涉才刚刚启程。燃石医学将会用科学守护生命之光！

Founded in March 2014, Firestone medicine has more than 10000 square meters of inspection institutes, R & D centers and GMP workshops in Beijing, Shanghai and Guangzhou. Firestone medicine focuses on the guidance of individualized treatment of tumor patients, with the core of second-generation sequencing and medical bioinformatics, and the cornerstone of conventional tumor molecular pathological detection, to create a one-stop solution for clinical detection service and scientific research of individualized treatment of tumor. Firestone medicine has a professional bioinformatics analysis and R & D team, as well as an industry team in operation management. Burn stone medicine is a third-party clinical laboratory with clinical medicine department. At the beginning of the company's establishment, it obtained a joint investment of 43 million yuan from the venture capital organization northern lights venture capital and Lenovo star. This fund is invested in laboratory construction and product research and development by Firestone medicine, and it's hard work and harvest. Under the leadership of Firestone team, Han Yusheng, founder of Firestone medicine, cut through thorns on the road of clinical transformation of tumor individualized treatment, promoting the transformation of second-generation sequencing technology in the field of tumor clinical diagnosis. At present, Firestone medicine has developed more than 30 detection products for different types of cancer and different clinical stages, involving early screening, benign and malignant judgment, concomitant detection of targeted drug use, tumor recurrence monitoring and tumor genetic detection. At the same time, Firestone medical actively seeks deep cooperation with domestic medical institutions, international equipment manufacturers and pharmaceutical companies, with strong R & D capabilities, excellent product design and excellent product performance, it has won the favor of many medical experts and industry leading companies, and has reached strategic cooperation with Illumina, AstraZeneca pharmaceutical, Agilent and ctong. In addition, Firestone medicine provides a one-stop ngs platform solution to promote the implementation of NGS detection in the pathology department of the hospital, benefiting more cancer patients. At present, burnstone is a tumor application direction NGS company that has entered the special approval procedure for innovative medical devices through the review of the State Food and Drug Administration (CFDA), and has recently obtained the first acceptance notice of medical device registration application issued by CFDA based on the products detected by ngs, tumor application direction of Illumina sequencing platform. The era of precision medicine is just coming, which indicates that our long journey has just begun. Burning stone medicine will protect the light of life with science!

本文链接： https://brand.waitui.com/adaca84fc.html 联系电话：请联系客服添加联系邮箱：请联系客服添加